of extra life with side effects which are a waste of money.
Sure the price will plummet but JNJ has ARN509 ready for approval and it is better than all the competition.
MDVN owns half of one drug , Xtandi, which is not nearly as good as JNJ;s successor to Xtandi, that is called ARN 309. JNJ owns ARN309 which is more effective, cheaper to make and has less side effects than Xtandi.
Zytiga is going off patent next year so JNJ can take over the whole market.